Edesa Biotech is trading at $5.05, up 5.59%, amid strong biotech-sector momentum.
- XBI rose 2.75% during regular trading, supporting a sector-driven explanation.
- No confirmed company-specific announcement was identified for September 2, 2026; the latest notable corporate development was the stale $25 million public offering, announced August 19–20.
- Biotech sentiment also benefited from patent news and broader positive momentum, including a major move in Purple Biotech.